On Dec 26, Baiyun district and BioIsland Lab jointly established the BioIsland Laboratory (Guangdong) Life Health Industry Investment Fund partnership enterprise.

The investors are Guangzhou Financial Holdings Group, Guangzhou Baiyun Financial Technology Holdings Group, and Guangzhou Baiyun Industrial Investment Group.

The BioIsland Lab. [Photo/WeChat account: gz_baiyunfabu]

Guangzhou Financial Holdings Group is a local financial holding group with the highest credit rating and most comprehensive array of financial licenses in the nation, while also ranking at the forefront in terms of assets.

Founded in 2017, BioIsland Lab focuses on technology transfer and industrial incubation in the biopharmaceutical field, aiming to promote technological breakthroughs and industrial development.

The collaboration aims to nurture innovative and competitive enterprises in the life health sector, promote innovative transformation in the biopharmaceutical industry, advance breakthroughs in cutting-edge areas of the biopharmaceutical industry, and improve the system for commercializing scientific research achievements.

Baiyun's biopharmaceutical industry has stabilized at an output of over 30 billion yuan ($4.11 billion), hosting institutions like Guangzhou University of Chinese Medicine, Nanfang Hospital, and the Greater Bay Area Center for Brain Research, forming a complete chain of medical industry leaders focusing on everything from research and development to production and distribution.

In the future, the collaboration will deepen cooperation in investment, scientific research achievement commercialization, and talent development, which in turn will accelerate the local implementation of laboratory results, helping Baiyun become a hub for innovation and industrial development in the biopharmaceutical field.